​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie (ABBV) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $256.92, with a high of $298.00 and a low of $223.00. This represents a 14.30% increase from the last price of $224.77.

$150 $180 $210 $240 $270 $300 High: $298 Avg: $256.92 Low: $223 Last Closed Price: $224.77

ABBV Stock Rating

AbbVie stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (68.29%), 12 Hold (29.27%), 1 Sell (2.44%), and 0 Strong Sell (0.00%).

Buy
Total 41 1 12 28 Strong Sell Sell Hold Buy Strong Buy

ABBV Price Target Upside V Benchmarks

TypeNameUpside
StockAbbVie14.30%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks9.12%

Price Target Trends

1M3M12M
# Anlaysts2727
Avg Price Target$266.50$265.14$258.15
Last Closing Price$224.77$224.77$224.77
Upside/Downside18.57%17.96%14.85%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 268168--32
May, 268169--33
Apr, 268149--31
Mar, 268139-131
Feb, 266139-129
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2026Evercore ISI$235.00$212.0510.82%4.55%
May 14, 2026Piper Sandler$298.00$208.5042.93%32.58%
Apr 30, 2026Morgan Stanley$278.00$212.1531.04%23.68%
Apr 23, 2026Piper Sandler$294.00$200.4946.64%30.80%
Apr 20, 2026Canaccord Genuity$262.00$203.7128.61%16.56%
Apr 10, 2026Vamil DivanGuggenheim$249.00$210.1518.49%10.78%
Feb 24, 2026Trung HuynhRBC Capital$260.00$228.4413.82%15.67%
Feb 19, 2026Barclays$275.00$224.3522.58%22.35%
Feb 18, 2026Piper Sandler$299.00$232.8628.40%33.02%
Feb 05, 2026UBS$230.00$217.425.79%2.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2026Piper SandlerOverweightOverweighthold
Apr 30, 2026Morgan StanleyOverweightOverweighthold
Apr 10, 2026GuggenheimBuyBuyhold
Mar 12, 2026GuggenheimBuyBuyhold
Mar 09, 2026William BlairOutperformOutperformhold
Mar 09, 2026BMO CapitalOutperformOutperformhold
Feb 24, 2026RBC CapitalOutperformOutperforminitialise
Feb 19, 2026BarclaysOverweightOverweightinitialise
Feb 18, 2026Piper SandlerOverweightOverweighthold
Feb 05, 2026BernsteinMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.48$6.65$2.73$2.40$2.38---
Avg Forecast$12.68$13.76$11.13$10.94$12.19$13.70$15.05$16.61
High Forecast$12.93$14.12$11.24$11.61$12.77$18.63$18.63$16.97
Low Forecast$12.43$13.34$11.08$10.67$11.57$7.28$7.23$15.93
Surprise %-48.90%-51.67%-75.47%-78.06%-80.48%---

Revenue Forecast

$50B $55B $60B $65B $70B $75B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$56.20B$58.05B$54.32B$56.33B$61.16B---
Avg Forecast$56.23B$58.27B$54.05B$56.04B$59.15B$63.51B$67.43B$71.61B
High Forecast$57.10B$59.43B$54.35B$56.19B$59.78B$63.52B$67.44B$72.82B
Low Forecast$55.40B$56.89B$53.94B$55.94B$58.25B$63.49B$67.41B$69.37B
Surprise %-0.07%-0.37%0.50%0.53%3.40%---

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.54B$11.84B$4.86B$4.28B$4.23B---
Avg Forecast$11.26B$13.10B$4.82B$19.75B$21.58B$14.78B$19.27B$29.44B
High Forecast$13.51B$15.72B$5.78B$20.59B$22.64B$33.03B$33.02B$30.08B
Low Forecast$9.01B$10.48B$3.86B$18.91B$20.51B$12.90B$12.83B$28.24B
Surprise %2.52%-9.67%0.89%-78.34%-80.41%---

ABBV Forecast FAQ

Is AbbVie stock a buy?

AbbVie stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that AbbVie is a favorable investment for most analysts.

What is AbbVie's price target?

AbbVie's price target, set by 41 Wall Street analysts, averages $256.92 over the next 12 months. The price target range spans from $223 at the low end to $298 at the high end, suggesting a potential 14.30% change from the previous closing price of $224.77.

How does AbbVie stock forecast compare to its benchmarks?

AbbVie's stock forecast shows a 14.30% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (9.12%).

What is the breakdown of analyst ratings for AbbVie over the past three months?

  • June 2026: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 24.24% Strong Buy, 48.48% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 25.81% Strong Buy, 45.16% Buy, 29.03% Hold, 0% Sell, 0% Strong Sell.

What is AbbVie’s EPS forecast?

AbbVie's average annual EPS forecast for its fiscal year ending in December 2026 is $13.7, marking a 475.63% increase from the reported $2.38 in 2025. Estimates for the following years are $15.05 in 2027, and $16.61 in 2028.

What is AbbVie’s revenue forecast?

AbbVie's average annual revenue forecast for its fiscal year ending in December 2026 is $63.51B, reflecting a 3.84% increase from the reported $61.16B in 2025. The forecast for 2027 is $67.43B, and $71.61B for 2028.

What is AbbVie’s net income forecast?

AbbVie's net income forecast for the fiscal year ending in December 2026 stands at $14.78B, representing an 249.73% increase from the reported $4.23B in 2025. Projections indicate $19.27B in 2027, and $29.44B in 2028.